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Abstract. Therapy  related  myeloid  malignancies  are  an  increasingly  recognized  tr
complication in patients undergoing therapy for multiple myeloma. The main predisposing factors 
are the alkylating agents, topoisomerase II inhibitors and radiotherapy, but recently questions have 
been raised regarding the immunomodulatory agent le
antimyeloma  agents  in  the  context  of  therapy  related  myeloid  malignancies.  The  duration  of 
treatment and the time from diagnosis  are the  main contributing factors in alkylating  induced 
myeloid malignancies which occur 5
being the characteristic finding. High dose therapy (HDT) does not seem to be a major contributing 
factor per se in multiple myeloma. In a number of large published series, all the factors re
therapy-induced myelodysplasia were defined prior to HDT. Topoisomerase II inhibitors induce 
mainly  acute  leukemias  which  invariably  correlate  with  dysregulation  of  the  MLL  gene. 
Radiotherapy causes therapy related myelodysplasia if applied in b
especially if combined with chemotherapy. Therapy related myeloid malignancies generally herald 
a poor prognosis. Karyotypic abnormalities seem to be the main prognostic factor. In all cases the 
risk for therapy related myeloid malignancies drops sharply by 10 years after the treatment.
Introduction. The  problem  of  therapy  related 
myelodysplastic syndromes  (t-MDS)  and  acute 
myeloid leukemia (t-AML) in the context of cytotoxic 
chemotherapy  is  perhaps  as  old  as  the  cytotoxic 
chemotherapy itself
1 and it is part of the more general 
problem  of  the  second  malignancies  after  cytotoxic 
chemotherapy.
2 It  is  a  well  known  fact  that  as  the 
overall survival (OS) for a malignant disease increases 
due to the treatment done, so the late effects of this 
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Therapy  related  myeloid  malignancies  are  an  increasingly  recognized  tr
complication in patients undergoing therapy for multiple myeloma. The main predisposing factors 
are the alkylating agents, topoisomerase II inhibitors and radiotherapy, but recently questions have 
been raised regarding the immunomodulatory agent lenalidomide. Little is known about the new 
antimyeloma  agents  in  the  context  of  therapy  related  myeloid  malignancies.  The  duration  of 
treatment and the time from diagnosis  are the  main contributing factors in alkylating  induced 
cur 5-10 years after treatment, chromosome 5 and 7 abnormalities 
being the characteristic finding. High dose therapy (HDT) does not seem to be a major contributing 
in multiple myeloma. In a number of large published series, all the factors re
induced myelodysplasia were defined prior to HDT. Topoisomerase II inhibitors induce 
mainly  acute  leukemias  which  invariably  correlate  with  dysregulation  of  the  MLL  gene. 
Radiotherapy causes therapy related myelodysplasia if applied in bone marrow producing areas, 
especially if combined with chemotherapy. Therapy related myeloid malignancies generally herald 
a poor prognosis. Karyotypic abnormalities seem to be the main prognostic factor. In all cases the 
malignancies drops sharply by 10 years after the treatment.
The  problem  of  therapy  related 
MDS)  and  acute 
AML) in the context of cytotoxic 
chemotherapy  is  perhaps  as  old  as  the  cytotoxic 
and it is part of the more general 
s  after  cytotoxic 
It  is  a  well  known  fact  that  as  the 
overall survival (OS) for a malignant disease increases 
due to the treatment done, so the late effects of this 
treatment become much more evident with 
of time.
3
Multiple Myeloma (MM) is the second most prevale
hematological malignancy in the Western World
last  15  years.  Since  the  beginning  of  the  era  of 
chemotherapeutical agents in the 70’s where the rate of 
complete remission (CR) for MM was below 3%, with 
the incorporation of tandem autologous hematopo
cell  –supported  high  dose  therapy  (HDT)
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complication in patients undergoing therapy for multiple myeloma. The main predisposing factors 
are the alkylating agents, topoisomerase II inhibitors and radiotherapy, but recently questions have 
nalidomide. Little is known about the new 
antimyeloma  agents  in  the  context  of  therapy  related  myeloid  malignancies.  The  duration  of 
treatment and the time from diagnosis  are the  main contributing factors in alkylating  induced 
10 years after treatment, chromosome 5 and 7 abnormalities 
being the characteristic finding. High dose therapy (HDT) does not seem to be a major contributing 
in multiple myeloma. In a number of large published series, all the factors related with 
induced myelodysplasia were defined prior to HDT. Topoisomerase II inhibitors induce 
mainly  acute  leukemias  which  invariably  correlate  with  dysregulation  of  the  MLL  gene. 
one marrow producing areas, 
especially if combined with chemotherapy. Therapy related myeloid malignancies generally herald 
a poor prognosis. Karyotypic abnormalities seem to be the main prognostic factor. In all cases the 
malignancies drops sharply by 10 years after the treatment.
treatment become much more evident with the advent 
Multiple Myeloma (MM) is the second most prevalent 
malignancy in the Western World
4 the 
last  15  years.  Since  the  beginning  of  the  era  of 
chemotherapeutical agents in the 70’s where the rate of 
complete remission (CR) for MM was below 3%, with 
the incorporation of tandem autologous hematopoietic 
supported  high  dose  therapy  (HDT)
5,6 and  the Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
newer  agents  as  thalidomide,  lenalidomide  and 
bortezomib, the rate of CR has increased to over 80% 
under  the  Total  Therapy  TT3  protocol,
7 making  the 
MM  median  OS  well  over  the  past  three  year 
landmark. In fact 10-year survivals of over 30% have 
been observed.
7 It is thus a natural consequence that the 
problem  of  t-MDS  and  t-AML  becomes  significant, 
requiring more attention form a biological perspective 
and likely requires special therpuetic considerations.
Epidemiology.  It  is  rather  appropriate  that  if  one 
considers and examines the epidemiological data of t-
MDS in MM to firstly acknowledge the fact that MDS 
and MM can co-exist de novo. Both the morphological
8
and the  cytogenetic
9 evidence of this fact have been 
well described , with the cytogenetic anomalies seen  in 
~4% of the total MM patient population and having a 
distinctly different prognosis from the rest of the MM 
subtypes.
9 In a series  of 648 MM  patients that were 
enrolled  in  two  non-HDT  British  Medical  Research 
Council trials,
10 the  5-year actuarial prevalence  and 
the  8-year   prevalence  of t-MDS were 3% and 10% 
respectively   (FAB  morphological  criteria  were  used 
for t-MDS and t-AML diagnosis). This series brought 
to  the  forefront,  the  issue  of  MM-therapy  related 
myeloid  neoplasms,  a  fact  that  was  preciously  well 
known  in  the  context  of  other  hematologic 
malignancies.  The  Arkansas  group  reported  on  the 
cytogenetically defined MDS of more than 3000 MM 
patients  that  underwent  HDT
11 and  reported  a 
prevalence  of  cytogenetically  defined  MDS  of  3%. 
Most  of  the  cytogenetic  abnormalities  (68%)  were 
transient and clinical t-MDS and t-AML developed in 
26  patients.  It  is  therefore  evident  that  there  is  a 
discrepancy of the reported prevalence and incidence 
of t-MDS in the various big series of the MM patients. 
Given the available knowledge on the main causes of t-
MDS, one has to evaluate the incidence of MDS in the 
context of the therapeutic regimen given.
Conventional  Chemotherapy  and  t-MDS  in  MM. 
The causative relationship of alkylating therapy in MM 
and t-MDS has been acknowledged as early as in the 
1970s.
13,14 The widespread use of alkylating agents in 
various  hematological  and  non  hematological 
malignancies has resulted in valuable knowledge of the 
characteristics of the alkylating induced t-MDS. It is 
occurring mainly as a late event of the chemotherapy 
with a characteristic latency of 5-10 years.
15 Patients 
will present with t-MDS and evidence of bone marrow 
failure with at least one cytopenias while a minority 
will  present  as  t-AML  or  t-myeloproliferative /
myelodysplastic  syndrome.
16 This  category  is 
commonly associated with unbalanced loss of genetic 
material,  often  involving  chromosomes  5  and/or  7, 
although  that  is  not  universal.
16 The  decades  of 
therapeutic  experience  has  also  contributed  the 
knowledge that it is the amount of time and cumulative 
dosing  of  these  agents  and  not  the  intensity  of  the 
therapy that contributes to the development of t-MDS. 
This  fact  is  well  established  in  many  malignancies
17
and is also evident in the MM population.
10 Also well 
established is the knowledge that all alkylating agents 
are  not  the  same  in  their  leukaemogenic  potential. 
Melphalan  and  BCNU  are  considered  more 
leukaemogenic  than  cyclophosphamide  in  general
18
and  this  fact  has  also  been  established  also  in  MM 
patients treated with these drugs.
10 The combination of 
alkylating  agents  and  radiotherapy  increases  the 
incidence of t-MDS.
16
The  second  category  of  t-MDS  related  to  the 
conventional  chemotherapy  is  related  to  the 
topoisomerase  II  inhibitors,  namely  adriamycin, 
etoposide,  chemotherapeutics  that  interact  through 
DNA  topoisomerase  II.  This  category  of 
chemotherapeutics has long been successfully used in 
the  treatment  of  MM.  The  t-MDS/AML  that  they 
produce has a latency period of 1-5 years, usually does 
not present as a t-MDS but as an overt t-AML from the 
beginning  and  is  often  associated  with  balanced 
chromosomal  translocation.
16,17 The  amount  of 
cumulative dosage is equivocal and in the setting of the 
therapy  of  other  hematological  malignancies  several 
regimen-related factors, as the schedule and concurrent 
use  of  asparaginase  and  G-SCF,  are  important  in 
determining the relative risk.
18,19 Especially etoposide 
has strictly been associated with translocations of the 
MLL  gene  on  chromosome  band  11q23.  MLL  is  a 
critical  transcription regulator  and  the  fact that  there 
are over 40 partner genes in reciprocal translocations 
found in MDS/AML, suggests that it holds a crucial 
role  in  the  pathogenesis  of  t-MDS/AML  and 
MDS/AML in general. 
In practice however most MM patients have received 
polychemotherapy of the above substances/modalities 
either concurrently or subsequently. The boundaries of 
the  chromosomal,  clinical  and  laboratory 
characteristics  of  the  resulting  t-MDS/AML 
characteristics  regarding  the  causal  chemotherapeutic 
are not always sharp.
11
t-MDS/AML and HDT in MM. HDT has become the 
standard of care in the management of younger patients 
with  symptomatic  or  progressive  MM.
20,21 Tandem 
autotransplantation has doubled survival in relationship 
to standard-dose therapy.
22 Sizable series have reported 
on the development of t-MDS/AML in the context of 
HDT for Hodgkin, non-Hodgkin lymphoma as well as 
MM.
11,23,24 There is a clear tendency for attribution of t-
MDS/AML, at least in the Hodgkin and non-Hodgkin Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
lymphomas,  in  HDT.  Since  standard  dose  regimens 
precede autologous peripheral blood stem cell (PBSC) 
collection and HDT, it is unclear whether the t-MDS is 
associated with HDT or the preceding chemotherapy. 
Primary HDT after non stem cell damaging vincristine 
– adriamycin- dexamethasone (VAD) therapy resulted 
in an incidence of t-MDS at 0% at 4.7 years.
25 In the 
biggest  HDT  MM  series  reported  till  now
11
multivariate  analysis  showed  that  the  t-MDS/AML 
development was correlated with age -15% in 10 years 
for the older patients (>65 years), poor (<2.5x 10
6/kg) 
PBSC collection, time interval between the preceding 
chemotherapy and HDT reflecting longer pre transplant 
chemotherapeutic exposure and low platelet recovery 3
months  after  the  first  transplantation  (<150x10
9/kg). 
The type of the HDT regimen was not significant in 
terms of subsequent t-MDS/AML development. From 
the  aforementioned  it  appears  that  HDT  is  likely  a 
contributing factor in t-MDS/AML, along with a host
of other important ones. The later is supported from the 
fact  that  studies  in  lymphoma  patients  that  applied 
fluorescence in situ hybridization (FISH) analysis for 
the detection of MDS lesions in interphase cells, found 
that such abnormalities were already present in PBSCs 
prior  to  HDT  and  were  similar  or  identical to  those 
subsequently detected after HDT.
26 Thus the question 
of the main contributing factor remains still open and 
could very well be that the main contribution of HDT 
to  t-MDS/AML  in  MM  is  improvement  in  overall 
survival and patient longevity. 
Newer Therapies and t-MDS in MM. Very little is 
known about the contribution or not to t-MDS of the 
newer MM therapies. There were not differences in the 
incidence  of  t-MDS  between  the  thalidomide  and 
control arm in the Arkansas Total Therapy 2 trial.
11The 
recent reports on the association of lenalidomide with 
myeloid  malignancies  have  born  mixed  results.  The 
IFM  2005-02  study
27  and  CALGB  100104  study
28
reported  increased  incidence  of  second  primary 
malignancies, including myeloid  malignanices, in the 
order of 5.5%-6.5%. In the MM-015 study, Palumbo et 
al
29 reported  a  0.7%  incidence  of  t-AML/t-MDS  in 
MM  transplant  ineligible  patients  with  use  of 
lenalidomide combined with melphalan/prednisone and 
receiving  additional  lenalidomide  maintenance, 
compared  with  those  receiving  melphalan/prednisone 
alone.  This  has  given  rise  to  the  debate  of  optimal 
duration  of  maintenance  with  lenalidomide,  as  it 
clearly has shown progression free survival benefit in 
MM.  To  date,  there  have  no  reports  regarding 
bortezomib in t-MDS/t-AML development in MM or 
lymphoma patients.
Therapeutic Modalities and Future Directions. It is 
crucial for anyone to realize that preventing is far better 
than treating! Present and future efforts have to be -at 
least partially- directed towards the maximum effective 
anti-MM therapy with the lowest t-MDS potential. For 
conventional  chemotherapy  cumulative  experience 
favors the short exposure to alkylating agents without 
intensity of treatment being a worrying factor in terms 
of t-MDS development. Radiotherapy perhaps should 
better  be  avoided  upfront  and  concurrently  with 
chemotherapy  at  least  in  bone marrow  producing 
regions.  There  are  enough  data  to  support  its 
leukaemogenic potential but not enough data to support 
its superiority in MM treatment at least compared with 
other  therapeutic  modalities.  Bortezomib  and 
thalidomide seem rather safe agents in MM regarding 
t-MDS.
30 The  role  of  lenalidomide  in  t-MDS  in  the 
context of maintenance treatment in MM seems rather 
controversial. There is a clear need for more series with 
the maximum amount of uniformity for the rest of the 
MM  treatment  for  someone  to  draw  more  definite 
conclusions. 
Drug or xenobiotic metabolizing enzymes (DME) play 
central roles in the metabolism, biotransformation, and 
detoxification of xenobiotics and foreign compounds. 
They generally protect from potential harmful insults 
from  the  environment  and  also  influence  the 
metabolism  of  drugs  (Table  1).  Polymorphisms  of 
these genes have been associated with the development 
of  t-MDS/AML  relative  to  the  previous  cytotoxic 
therapy. Although some of the reports are conflicting, 
the hall concept appears to be a very promising sector 
of  pharmacogenomics  and  the  individualization  of 
cytotoxic therapy in general.
31
The prognosis of t-MDS/AML is generally considered 
poor. An overall 5-year survival of less than 10% is 
commonly reported.
15 It is strongly associated with the 
underlying  karyotypic  abnormality,  something  that 
recently has been recognized in de novo MDS also, as 
it is portrayed in the revised IPSS that showed in the 
last  International  MDS  Symposium  (ISMDS  2011, 
Edinburgh  May  18-21).  Cases  with  abnormalities  of 
chromosome 5 and/or 7 and a complex caryotype have 
a particular poor prognosis with a median survival of 
less  than  one  year  regardless  of  the  number  of 
myeloblasts present in  bone marrow biopsy at initial 
MDS  diagnosis.
32,33 Perhaps  for  these  patients,  an 
allogeneic  transplantation  should  be  strongly 
considered upfront. For not eligible patients autologous 
transplantation with PBSC collected early in the course 
of the patient could serve as an alternative. In the cases 
of  5q- chromosomal  abnormalities  lenalidomide  has 
proved a valuable drug in releaving the accompanying 
anemia  and  in  some  cases inducing  cytogenetic 
remission.
34 The  drug  can  be  given  also  to  non  5q-
MDS with a amount of myeloblasts <10% with good Mediterr J Hematol Infect Dis 2011; 3: Open Journal System















































results as long as the Gene Expression Profile of the 
MDS  resembles  the  one  of  5q- syndrome.
34 Hypo 
ethylating agents azacytidine and decitabine although 
have  promising  results  in  de  novo  high  IPSS  MDS, 
have not been tested enough in t-MDS/AML and the 
results  in  cases  with  7  monosomy  and  complex 
caryotype are rather disappointing. Perhaps their use is 
better  suited  for  cases  of  t-MDS  with  a  number  of 
myeloblasts>10%  and  karyotypic  abnormalities  that 
represent balanced translocations. This group can also 
benefit from the traditional chemotherapy approach at 
least  for  induction  and/or  salvage  chemotherapy  in 
terms of RAEB II MDS or t-AML. Of notice is the fact 
that the rare antracycline related Acute Promyelocytic 
Leukemias herald the exact same prognosis with the de 
novo ones,
35 a fact that highlights the importance of the 
underlying  karyotypic  abnormality  in  the  prognostic 
and therapeutical evaluation of t-MDS. Supportive care 
(erythropoietin  agents,  transfusion  policy,  iron 
chelating  therapy)  is  the  same  as  with  the  de  novo
MDS.
Conclusions. t-MDS  represents  a  real  and  emerging 
problem  in  MM  treatment.  As  the  median  MM  OS 
survival universally increases it will possibly establish 
further its presence in the MM course. Although the 
diagnostic, prognostic and therapeutic capabilities of t-
MDS and MDS in general are continuously expanding, 
one has to remember that “to prevent is always better 
than curing’’ meaning that a good amount of present 
and  future  efforts  has  to  be  concentrated  in  the 
recognition and improvement of the MM therapy with 
the  best  anti  myeloma  effect  and  the  fewer  t-MDS 
complications.
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